What is claimed is:

1. A compound having Formula (II), or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a pharmaceutically acceptable salt or a prodrug thereof,



(II),

wherein

m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

A is CR^3;

X is CR^1;

Q is CH or N;

M is $-NR^7-$;

L_1 is a bond, -NH- or $-CH_2-$;

each R^1 is independently H, D, F, Cl, Br, I, -CN, $-NO_2$, -OH, $-NH_2$, methyl, ethyl, $-CHF_2$ or $-CF_3$;

R^2 is $-CHF_2$;

R^3 is H;

each R^4 is independently H, D, F, Cl, Br, I, -CN, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl, C_{1-4} alkoxy or C_{1-4} haloalkoxy; or two R^4, together with the adjacent ring carbon atoms to which they are attached, form a substituted or unsubstituted benzene ring; and

each R^7 is independently H, D, F, Cl, Br, I, -CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl or 3- to 6-membered heterocyclyl.

2. The compound according to claim 1, wherein each R^4 is independently H, D, F, Cl, Br, I, -CN, methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, *t*-butyl, $-CH_2F$, $-CHF_2$, $-CF_3$, $-CH_2CHF_2$, $-CH_2CF_3$, $-CHFCF_3$, $-CF_2CHF_2$, $-CF_2CF_3$, methoxy, ethoxy, *n*-propoxy, *i*-propoxy, *n*-butoxy, *i*-butoxy, *t*-butoxy, $-OCHF_2$, $-OCF_3$ or $-OCH_2CF_3$; or two R^4, together with the adjacent ring carbon atoms to which they are attached, form a substituted or unsubstituted benzene ring.

3. The compound according to claim 1 or claim 2, wherein each R^7 is independently H, D, methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, *t*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, oxetanyl, thietanyl, pyrrolidyl or tetrahydrofuryl.

4. The compound according to any one of claims 1-3 having one of the following structures, or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a pharmaceutically acceptable salt or a prodrug thereof,


(1),


(2),


(3),


(4),


(5),


(6),


(7),


(8),


(9),


(10),


(14),


(15),


(16),



(17),



(18),



(19),



(20),



(21),



(22),



(23),



(24),



(25),



(26),



(27),



(28),



(29),



(30),



(31),



(32),



(33),



(34),



(35),



(36),



(37),



(38),



(39),



(40),



(41),



(42),



(43),



(44),



(45),



(46),



(47),



(48),



(49),



(50),



(51),



(52),



(53),



(54),



(61),



(62),



(63),



(64),



(65),



(66),



(67) ,



(68) ,



(69) ,



(70) ,



(71) ,



(72) ,



(73) ,



(74) ,



(75) , or



(76) .

5. A pharmaceutical composition comprising a compound according to any one of claims 1-4, and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.

6. The pharmaceutical composition according to claim 5 further comprising an additional therapeutic agent used for treating Alzheimer's disease, neuropathy or a

combination thereof.

7. The pharmaceutical composition according to claim 6, wherein the additional therapeutic agent is donepezil, nalmefene, risperidone, Vitamin E, SAM-760, AVN-211, AVN-101, RP-5063, tozadenant, PRX-3140, PRX-8066, RVT-101, naluzaton, idalopirdine, tacrine, rivastigmine, galantamine, memantine, mirtazapine, venlafaxine, desipramine, nortriptyline, zolpidem, zopiclone, nicergoline, piracetam, selegiline, pentoxifylline or a combination thereof.

8. Use of a compound according to any one of claims 1-4 or a pharmaceutical composition according to any one of claims 5-7 in the manufacture of a medicament for preventing, treating or lessening a 5-HT_6 receptor-mediated disease.

9. The use according to claim 8, wherein the 5-HT_6 receptor-mediated disease is a central nervous system disorder, a gastrointestinal disorder or obesity.

10. The use according to claim 9, wherein the central nervous system disorder is an attention deficit hyperactivity disorder, anxiety, a stress-related disorder, schizophrenia, an obsessive-compulsive disorder, manic depression, a neurological disorder, a memory disorder, an attention deficit disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease or Huntington's chorea.